GLP-1 Receptor Agonist Safety: Counterfeit Drug Risks
Comments Off on GLP-1 Receptor Agonist Safety: Counterfeit Drug Risks
June 14, 2026
Counterfeit GLP-1 medications present serious safety risks including inconsistent dosing and contamination. These unauthorized products can cause adverse events and treatment failures. Clinicians must counsel patients on obtaining GLP-1 drugs from…
GLP-1 Receptor Agonist Safety: FDA Warning Letter Analysis
Comments Off on GLP-1 Receptor Agonist Safety: FDA Warning Letter Analysis
April 24, 2026
GLP-1 receptor agonist manufacturing compliance is critical for ensuring medication safety and supply reliability. The FDA warning letter highlights regulatory concerns affecting product quality. Clinicians should consider these compliance issues when…